Trials / Completed
CompletedNCT00446446
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Phase 2, Single-Arm, Open-Label, Multi-Center Trial of Second-Line Panitumumab Monotherapy in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To estimate the effect of second-line panitumumab monotherapy on objective response in patients with metastatic or recurrent squamous cell carcinoma of head and neck (SCCHN).
Conditions
- Cancer
- Carcinoma
- Head and Neck Cancer
- Metastases
- Metastatic Cancer
- Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
- Oncology
- Squamous Cell Carcinoma
- Tumors
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Panitumumab | Panitumumab was administered over a 1 hour intraveneous (IV) infusion at a dose of 9 mg/kg every 21 days. |
Timeline
- Start date
- 2007-10-30
- Primary completion
- 2010-12-15
- Completion
- 2017-11-29
- First posted
- 2007-03-12
- Last updated
- 2022-10-05
- Results posted
- 2016-03-07
Source: ClinicalTrials.gov record NCT00446446. Inclusion in this directory is not an endorsement.